IRIS
TISEO, Marcello
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.884
AS - Asia 15.694
EU - Europa 9.129
SA - Sud America 2.706
AF - Africa 932
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 8
AN - Antartide 1
Totale 44.382
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.483
SG - Singapore 6.276
CN - Cina 3.399
VN - Vietnam 2.673
BR - Brasile 2.028
IT - Italia 1.947
IE - Irlanda 1.671
SE - Svezia 1.408
HK - Hong Kong 1.339
DE - Germania 718
FR - Francia 718
FI - Finlandia 625
ZA - Sudafrica 601
NL - Olanda 551
IN - India 388
GB - Regno Unito 312
RU - Federazione Russa 293
TR - Turchia 265
AR - Argentina 248
BD - Bangladesh 211
AT - Austria 203
CA - Canada 172
UA - Ucraina 155
ID - Indonesia 147
MX - Messico 140
IQ - Iraq 121
EC - Ecuador 115
JP - Giappone 113
PK - Pakistan 102
PL - Polonia 89
PH - Filippine 87
CO - Colombia 84
ES - Italia 83
CI - Costa d'Avorio 81
KR - Corea 77
BE - Belgio 74
CZ - Repubblica Ceca 74
MA - Marocco 60
VE - Venezuela 60
CL - Cile 54
UZ - Uzbekistan 53
SA - Arabia Saudita 46
PY - Paraguay 45
TH - Thailandia 44
KE - Kenya 42
TN - Tunisia 38
JO - Giordania 37
IR - Iran 34
MY - Malesia 33
LT - Lituania 29
TW - Taiwan 29
AZ - Azerbaigian 28
EG - Egitto 28
KZ - Kazakistan 25
PE - Perù 25
AU - Australia 24
ET - Etiopia 24
BO - Bolivia 22
RO - Romania 21
AE - Emirati Arabi Uniti 19
UY - Uruguay 19
GR - Grecia 18
IL - Israele 18
NP - Nepal 17
BG - Bulgaria 15
LU - Lussemburgo 14
OM - Oman 14
CH - Svizzera 13
PA - Panama 13
AL - Albania 12
BH - Bahrain 12
CR - Costa Rica 12
JM - Giamaica 12
PS - Palestinian Territory 12
DO - Repubblica Dominicana 11
DZ - Algeria 11
HN - Honduras 11
SN - Senegal 10
LB - Libano 9
SI - Slovenia 9
SY - Repubblica araba siriana 9
BY - Bielorussia 8
NG - Nigeria 8
RS - Serbia 8
DK - Danimarca 7
GE - Georgia 7
KG - Kirghizistan 7
PT - Portogallo 7
QA - Qatar 7
BA - Bosnia-Erzegovina 6
BB - Barbados 6
HU - Ungheria 6
KW - Kuwait 6
LV - Lettonia 6
MD - Moldavia 6
SV - El Salvador 6
AM - Armenia 5
GT - Guatemala 5
KH - Cambogia 5
LY - Libia 5
Totale 44.283
Salva come PNG Salva come JPEG
Città #
Singapore 3.298
Ashburn 2.111
Chandler 1.715
San Jose 1.680
Dublin 1.659
Dallas 1.284
Hong Kong 1.263
Beijing 857
Ho Chi Minh City 839
Santa Clara 823
Hanoi 608
Boardman 589
Johannesburg 551
Parma 482
Lauterbourg 412
New York 393
Los Angeles 375
Ann Arbor 363
Princeton 358
Shanghai 330
Munich 260
Dearborn 256
Nanjing 194
Council Bluffs 192
Des Moines 184
Helsinki 179
Wilmington 175
São Paulo 169
Vienna 164
Moscow 163
Hefei 160
Milan 156
Columbus 149
Izmir 142
Jacksonville 131
Da Nang 123
Bologna 114
Buffalo 114
Haiphong 105
Chicago 103
Seattle 103
Bremen 101
Jakarta 99
The Dalles 97
Marseille 96
Frankfurt am Main 89
Jinan 86
Tokyo 85
Rio de Janeiro 82
Abidjan 81
San Mateo 74
Nuremberg 73
Warsaw 70
Shenyang 64
Turku 63
Amsterdam 62
Brussels 62
London 62
Nanchang 60
Denver 59
Redmond 59
Tianjin 59
Atlanta 58
Guangzhou 58
Chennai 57
Montreal 55
Kunming 54
Hebei 53
Rome 53
Orem 52
Belo Horizonte 51
Fremont 50
Toronto 50
Brno 49
Changsha 48
Baghdad 47
Biên Hòa 47
Brooklyn 46
Hải Dương 46
Houston 45
Phoenix 45
Tashkent 44
Curitiba 43
Modena 43
Bengaluru 42
Mexico City 42
Poplar 42
Seoul 41
Stockholm 41
Pune 40
Norwalk 38
Dhaka 36
Quito 36
Brasília 34
Nairobi 34
Amman 33
Lahore 33
San Francisco 33
Boston 32
Can Tho 32
Totale 26.592
Salva come PNG Salva come JPEG
Nome #
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 258
LINFOCITI INFILTRANTI IL TUMORE, BAP-1, VEGFR-2 E IGF-1R NEL MESOTELIOMA PLEURICO MALIGNO 258
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 246
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 243
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 239
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors 217
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 214
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 210
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 210
Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients 209
Isolation and characterization of circulating tumor cells in advanced squamous-cell carcinoma of the lung 206
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 205
227P Sexual dimorphism in immune profile of early and advanced NSCLC 200
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 198
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 193
Characterization of gefitinib uptake in NSCLC cell lines 189
The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors 189
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 188
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 185
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method 184
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 182
Accuracy of fine needle aspiration cytology in the pathological typing of non-small cell lung cancer. 181
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 180
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 177
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 177
INTEGRATION OF TISSUE PD-1/PD-L1 IMMUNE CHECKPOINT WITH COMPUTED TOMOGRAPHY (CT) BASED TEXTURE ANALYSIS EXHIBITS HIGH PROGNOSTIC IMPACE ON SURGICALLY RESECTED NON SMALL CELL LUNG CANCER (NSCLC) 176
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 176
Low PD-1 expression in Cytotoxic CD8+ Tumor infiltrating Lymphocytes Confers an Immune Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value 176
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 175
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 174
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 173
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 173
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 172
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 170
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 169
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 168
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY 167
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 167
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 166
ACCURACY OF CYTOLOGY IN THE IDENTIFICATION OF HISTOLOGIC SUBTYPE IN NON-SMALL CELL LUNG CANCER (NSCLC 165
Dataset on the identification of a prognostic radio-immune signature in surgically resected Non Small Cell Lung Cancer 165
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 164
The role of miRNA-221 and miRNA-126 in patients with benign metastasizing leiomyoma of the lung: an overview with new interesting scenarios 164
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 162
Advantages of multidetector row CT with multiplanar reformation in guiding percutaneous lung biopsies. 162
Isolation and characterization of H23 clones resistant to the KRASG12C inhibitors sotorasib and adagrasib 160
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 160
Widespread Nivolumab-induced Enteropathy in a Long Responder Non–Small-cell Lung Cancer Patient 160
Neoplasie del polmone in Neoplasie del Distretto Toracico 159
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 157
ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients 157
Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature 157
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 156
Aberrant expression of PTEN in squamous lung cancer cells: molecular analysis and impact on the synergistic combination of the targeted therapy with BKM120 and Defactinib 156
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 156
Gefitinib metabolism by CYP1A1 affects biological responses in NSCLC cell lines. 155
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 154
CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients 154
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 153
Prognostic value of [18F]FDG PET/CT parameters in surgically resected primary lung adenocarcinoma: a single-center experience 153
Integrated MRI–Immune–Genomic Features Enclose a Risk Stratification Model in Patients Affected by Glioblastoma 152
Longitudinal Changes of CT-radiomic and Systemic Inflammatory Features Predict Survival in Advanced Non–Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors 152
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 152
Spatial architecture of tumour-infiltrating lymphocytes as a prognostic parameter in resected non-small-cell lung cancer 150
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors 149
Predictive factors of diagnostic accuracy of CT-guided transthoracic fine-needle aspiration for solid noncalcified, subsolid and mixed pulmonary nodules. 148
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors 147
CT-guided biopsy of pulmonary nodules: Is pulmonary hemorrhage a complication or an advantage? 147
First-line immunotherapy in non-small cell lung cancer patients with poor performance status: A systematic review and meta-analysis 147
Multiple primary malignancies involving lung cancer: a single-center experience 145
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 144
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 144
Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC 144
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 144
IASLC and WHO 2004 Grading System as Prognostic Factors in 492 Cases of Pulmonary Adenocarcinoma 143
L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib 143
Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) 141
Curved Needles in CT-Guided Fine Needle Biopsies of Abdominal and Retroperitoneal Small Lesions 141
Reliability of EGFR and KRAS mutation analysis on fine-needle aspiration washing in non-small cell lung cancer 141
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 140
SMO mutations confer poor prognosis in malignant pleural mesothelioma 140
Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient 139
Transthoracic computed tomography-guided lung biopsy in the new era of personalized medicine 139
Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: A case report 138
Unraveling the link between cholesterol and immune system in cancer: From biological mechanistic insights to clinical evidence. A narrative review 137
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab 137
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 137
Asymptomatic pulmonary embolism in lung cancer: Prevalence and analysis of clinical and radiological characteristics in 141 outpatients 136
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 135
Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib 135
Monitoring cfDNA in plasma and in other liquid biopsies of advanced EGFR mutated NSCLC patients: A pilot study and a review of the literature 135
Bilateral Severe Corneal Ulcer in a Patient with Lung Adenocarcinoma Treated with Gefitinib 134
5P Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC 133
A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients? 133
PD-L1 OVEREXPRESSION INDUCES ANGIOGENIC CYTOKINE SECRETION AND ENDOTHELIAL CELL MIGRATION VIA STAT SIGNALLING. 132
Plasma and EBC microRNAs as early biomarkers of non-small-cell lung cancer 132
Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer 132
ANALYSIS OF MICRORNA EXPRESSION IN MALIGNANT PLEURAL MESOTHELIOMA, ASBESTOSIS AND BENIGN PULMONARY DISEASE: A PRELIMINARY STUDY 131
Comparison between epidermal growth factor receptor (EGFR) gene expression in primary non small cell lung cancer(NSCLC) and fine needle aspirates from distant metastatic sites. 131
Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs) 131
Totale 16.480
Salva come PNG Salva come JPEG
Categoria #
all - tutte 167.337
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 167.337
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021356 0 0 0 0 0 0 0 0 0 75 201 80
2021/20221.834 56 32 60 101 51 34 304 136 82 41 134 803
2022/20236.278 806 675 367 428 518 681 70 410 1.991 28 219 85
2023/20242.925 134 199 90 89 288 652 209 199 127 195 256 487
2024/20259.002 220 570 662 514 913 879 452 376 1.079 913 757 1.667
2025/202620.754 1.715 1.799 2.944 2.197 3.262 1.210 2.371 829 2.880 1.547 0 0
Totale 45.140